DDInter1620 DDInter648
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albendazole
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Picosulfuric acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN10A
SCN10A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN3A
SCN3A {u} (Gene) is bound by {v} (Compound) Zonisamide
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Entrectinib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Entrectinib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Entrectinib
Ropivacaine (Compound) binds SCN3A (Gene) and SCN3A (Gene) is bound by Zonisamide (Compound) and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib